The 8 analysts offering 12-month price forecasts for CytomX Therapeutics Inc have a median target of 3.25, with a high estimate of 8.00 and a low estimate of 1.63. The median estimate represents a +125.69% increase from the last price of 1.44.
The current consensus among 10 polled investment analysts is to Hold stock in CytomX Therapeutics Inc. This rating has held steady since July, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.30
Reporting Date Nov 08
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.